Tomaz Lunder1,2, Mateja S Zorko1,2, Natasa K Kolar3, Aleksandra B Suhodolcan1,2, Maruska Marovt4, Nada K Leskovec2,5, Pij B Marko4. 1. Department of Dermatovenereology, University Medical Centre Ljubljana, Ljubljana, Slovenia. 2. Medical Faculty, University of Ljubljana, Ljubljana, Slovenia. 3. Department of Dermatovenereology, Celje General Hospital, Celje, Slovenia. 4. Department of Dermatovenereology, University Medical Centre Maribor, Maribor, Slovenia. 5. Remeda, Medical Centre, Domzale, Slovenia.
Abstract
BACKGROUND: Drug survival is an important measure of successful treatment of patients with chronic diseases such as psoriasis. Therefore, the objective was to calculate drug survival and examine safety profile of biologics and immunomodulators (adalimumab, apremilast, etanercept, ixekizumab, infliximab, secukinumab, and ustekinumab) from the Slovenian National Registry of patients with moderate-to-severe psoriasis. METHODS: Data about the patients with moderate-to-severe plaque psoriasis treated with biologics were collected from 2005 until July 2018. Kaplan-Meier survival curves and Cox regression were used to calculate drug survival, where ustekinumab was selected as a reference. RESULTS: Overall, 1,606 patients were analyzed within 2,241 treatment episodes; adalimumab N = 831, apremilast N = 94, etanercept N = 101, ixekizumab N = 98, infliximab N = 164, secukinumab N = 340, and ustekinumab N = 613, respectively. Loss of efficacy was the most frequent reason for treatment discontinuation (contributing to 66.1% of all discontinuations). Ustekinumab was associated with the highest drug survival, meanwhile apremilast was the drug with the lowest survival rate compared to all others. Both IL-17 inhibitors, secukinumab and ixekizumab, showed similar survival rate. CONCLUSIONS: Ustekinumab was associated with the highest drug survival and most favorable safety profile compared to other biologics. Drug survival rates can be associated with the class effect of biological targets. Highest survival rate was observed for IL-12/23 inhibitor, followed by IL-17 and TNF-α inhibitors, and last by an immunomodulator such as apremilast. Adverse events occurred most frequently with TNF-α inhibitors.
BACKGROUND: Drug survival is an important measure of successful treatment of patients with chronic diseases such as psoriasis. Therefore, the objective was to calculate drug survival and examine safety profile of biologics and immunomodulators (adalimumab, apremilast, etanercept, ixekizumab, infliximab, secukinumab, and ustekinumab) from the Slovenian National Registry of patients with moderate-to-severe psoriasis. METHODS: Data about the patients with moderate-to-severe plaque psoriasis treated with biologics were collected from 2005 until July 2018. Kaplan-Meier survival curves and Cox regression were used to calculate drug survival, where ustekinumab was selected as a reference. RESULTS: Overall, 1,606 patients were analyzed within 2,241 treatment episodes; adalimumab N = 831, apremilast N = 94, etanercept N = 101, ixekizumab N = 98, infliximab N = 164, secukinumab N = 340, and ustekinumab N = 613, respectively. Loss of efficacy was the most frequent reason for treatment discontinuation (contributing to 66.1% of all discontinuations). Ustekinumab was associated with the highest drug survival, meanwhile apremilast was the drug with the lowest survival rate compared to all others. Both IL-17 inhibitors, secukinumab and ixekizumab, showed similar survival rate. CONCLUSIONS:Ustekinumab was associated with the highest drug survival and most favorable safety profile compared to other biologics. Drug survival rates can be associated with the class effect of biological targets. Highest survival rate was observed for IL-12/23 inhibitor, followed by IL-17 and TNF-α inhibitors, and last by an immunomodulator such as apremilast. Adverse events occurred most frequently with TNF-α inhibitors.
Authors: Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf Journal: JAAD Int Date: 2020-12-26
Authors: Kirk Geale; Ingrid Lindberg; Emma C Paulsson; E Christina M Wennerström; Anna Tjärnlund; Wim Noel; Dana Enkusson; Elke Theander Journal: Rheumatol Adv Pract Date: 2020-12-19
Authors: Roberta Ramonda; Mariagrazia Lorenzin; Antonio Carriero; Maria Sole Chimenti; Raffaele Scarpa; Antonio Marchesoni; Ennio Lubrano di Scorpaniello; Carlo Salvarani; Alberto Cauli; Angelo Semeraro; Leonardo Santo; Augusta Ortolan; Andrea Doria; Elena Fracassi; Giulia Virelli; Marco Masia; Rosalinda Fanizzi; Elisa Visalli; Giorgio Amato; Antonio Carletto; Rosario Foti Journal: RMD Open Date: 2021-02